APR APR 1994 PRADEMINE

$\begin{array}{ccc} 126 & 3-1 \bigcirc 99 \end{array}$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

		,,,,
In re Application of)	Examiner: 6/16/94
Patrick Casara)	Art Unit: 1204 America
Serial No.: 08/184,762)	i hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an
Filed: 01/19/94)	envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, on
Title: Novel Process for)	1 17 64

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

The Honorable Commissioner of Patents and Trademarks Washington, D.C., 20231

preparing 4-amino-5-hexenoic

Sir:

acid)

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

Applicants enclose herewith European Patent Application EP 0 177 807 written in German (hereafter "German Patent Application", reference B.3). Applicants also submit herewith what is believed to be the English language equivalent of the German Patent Application (U.S. Patent No. 4,668,433, reference A.4).

- [X] (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office action on the merits, whichever event occurs last.
- [] (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under \$1.113 or a notice of allowance under \$1.311, whichever occurs first.
 - (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
 - [] (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in \$1.56(c) more than

three months prior to the filing of this statement; or

 (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in \$1.17(p) and required by 37 C.F.R.
1.97(c) is authorized.

Respectfully submitted,

Carolyn D. Moon

Marion Merrell Dow Inc. 2110 E. Galbraith Road Cincinnati, Ohio 45215 Telephone (513) 948-7961

Registration No. 33,022 Attorney/Agent for Applicants

or

Marion Merrell Dow Research Institute - 16 Rue d'Ankara 67080 Strasbourg Cedex, France Tel. 33 88 41 45 38 Fax 33 88 61 39 43